Tel: 961 4 930252 - Email: info@pheniciagroup.com

Alfa Wassermann S.P.A - Italy

NIFEDICOR RETARD
NORMIX
VESSEL DUE F Capsules
VESSEL DUE F Inj.

Forms and presentation
Injectable solution IM and IV: Injectable ampoules: Box of 10.

Composition
Each ampoule contains: Sulodexide: 600 LSU.

Properties
Vessel Due F contains Sulodexide glycosaminglycan featuring a marked antithrombotic action either on arterial or venous systems. Several clinical studies based on parenteral and oral product’s administration show that the antithrombotic action of Sulodexide is due to the dose-dependent inhibition of some coagulative factors among which, first of all, the Xactivated factor, interference with thrombin remains instead at levels of low significance and the consequences of a coagulative action are generally avoided. Antithrombotic action is sustained even by the inhibition of platelet aggregation and by the activition of circulatory and wall fibrinolytic system. Sulodexide is also capable of normalizing altered viacosimetry parameters generally present in patients with vascular pathologies with thrombotic risk; this action mainly relies on reduced fibrinogen values. Sulodexide pharmacological profile described so far is completed with the normalization of altered lipidic values by the activation of lipoproteinlipase.

Indications
Vascular pathologie with thrombotic risk.

Contraindications
Individual hypersensitivity towards the product, towards heparin and heparin-like products. Diathesis and hemorrhagic diseases.

Precautions
In all cases where anticoagulant treatment is under way, hemocoagulative parameters should be monitored periodically.

Pregnancy and lactation
Pregnancy: Due to precautionary reasons, the administration of Vessel Due F to pregnant women is not recommended.

Side effects
Occasional reports of the following side effects: pain, burn and hematoma in the site of injection.
Rarely, there can be sensitization with cutaneous reaction or reaction in other seats.

Dosage and administration
1 ampoule daily, IM or IV.
It is generally suggested that ampoules be used to start treatment and that after 15-20 days it be continued with capsules for 30-40 days. The complete treatment cycle must be repeated at least twice yearly.
Depending on the physician’s judgement, the quality and frequency of the posology may vary.

Origin: Italy
Laboratories: Alfa Wassermann
Distributor: Droguerie Phenicia
Number & Year of Registration: 405402/2001